AFAmy Parker Fiebelkorn

Amy Parker Fiebelkorn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amy Parker Fiebelkorn has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Abdirahman Mahamud

    From the *National Center for Immunization and Respiratory Diseases; †Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ‡Guam Department of Public Health and Social Services; §Guam Memorial Hospital; ¶Guam Department of Education, Guam; ‖Division of Global Migration and Quarantine; and **Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Anna Lizama

    From the *National Center for Immunization and Respiratory Diseases; †Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ‡Guam Department of Public Health and Social Services; §Guam Memorial Hospital; ¶Guam Department of Education, Guam; ‖Division of Global Migration and Quarantine; and **Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Annakutty Md Mathew

    From the *National Center for Immunization and Respiratory Diseases; †Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ‡Guam Department of Public Health and Social Services; §Guam Memorial Hospital; ¶Guam Department of Education, Guam; ‖Division of Global Migration and Quarantine; and **Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Annette Aguon

    From the *National Center for Immunization and Respiratory Diseases; †Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ‡Guam Department of Public Health and Social Services; §Guam Memorial Hospital; ¶Guam Department of Education, Guam; ‖Division of Global Migration and Quarantine; and **Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication
  • Araceli Rey

    Epidemic Intelligence Service, Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

    1 shared publication
  • Carole Hickman

    From the *National Center for Immunization and Respiratory Diseases; †Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; ‡Guam Department of Public Health and Social Services; §Guam Memorial Hospital; ¶Guam Department of Education, Guam; ‖Division of Global Migration and Quarantine; and **Office of Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, GA

    1 shared publication

Latest Publications

    • 14 June 2013
      • Vol. 62  (4) , 1-34
    Top Cited Papers

    Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013 Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP)

    by Huong Q. McLean, Amy Parker Fiebelkorn, Jonathan L. Temte, Gregory S. Wallace

    This report is a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps. The report presents the recent revisions adopted by the Advisory Committee on Immunization Practices (ACIP) on October 24, 2012, and also summarizes all existing ACIP recommendations that have been published previously during 1998-2011 (CDC. Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1998; 47[No. RR-8]; CDC. Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR 2001; 50: 1117; CDC. Updated recommendations of the Advisory Committee on Immunization Practices [ACIP] for the control and elimination of mumps. MMWR 2006; 55: 629-30; and, CDC. Immunization of healthcare personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60[No. RR-7]). Currently, ACIP recommends 2 doses of MMR vaccine routinely for children with the first dose administered at age 12 through 15 months and the second dose administered at age 4 through 6 years before school entry. Two doses are recommended for adults at high risk for exposure and transmission (e.g., students attending colleges or other post-high school educational institutions, healthcare personnel, and international travelers) and 1 dose for other adults aged >= 18 years. For prevention of rubella, 1 dose of MMR vaccine is recommended for persons aged >= 12 months. At the October 24, 2012 meeting, ACIP adopted the following revisions, which are published here for the first time. These included: For acceptable evidence of immunity, removing documentation of physician diagnosed disease as an acceptable criterion for evidence of immunity for measles and mumps, and including laboratory confirmation of disease as a criterion for acceptable evidence of immunity for measles, rubella, and mumps. For persons with human immunodeficiency virus (HIV) infection, expanding recommendations for vaccination to all persons aged >= 12 months with HIV infection who do not have evidence of current severe immunosuppression; recommending revaccination of persons with perinatal HIV infection who were vaccinated before establishment of effective antiretroviral therapy (ART) with 2 appropriately spaced doses of MMR vaccine once effective ART has been established; and changing the recommended timing of the 2 doses of MMR vaccine for HIV-infected persons to age 12 through 15 months and 4 through 6 years. For measles postexposure prophylaxis, expanding recommendations for use of immune globulin administered intramuscularly (IGIM) to include infants aged birth to 6 months exposed to measles; increasing the recommended dose of IGIM for immunocompetent persons; and recommending use of immune globulin administered intravenously (IGIV) for severely immunocompromised persons and pregnant women without evidence of measles immunity who are exposed to measles. As a compendium of all current recommendations for the prevention of measles, rubella, congenital rubella syndrome (CRS), and mumps, the information in this report is intended for use by clinicians as baseline guidance for scheduling of vaccinations for these conditions and considerations regarding vaccination of special populations. ACIP recommendations are reviewed periodically and are revised as indicated when new information becomes available.


  • Epidemiology of a Mumps Outbreak in a Highly Vaccinated Island Population and Use of a Third Dose of Measles–Mumps–Rubella Vaccine for Outbreak Control—Guam 2009 to 2010

    by George E. Nelson, Annette Aguon, Engracia Valencia, Rita Oliva, Michele Leon Guerrero, Richard Reyes, Anna Lizama, Daryl Diras, Annakutty Md Mathew, E. Jessica Med Camacho, et al.

    Background: Despite high 2-dose measles-mumps-rubella (MMR) vaccine coverage, a large mumps outbreak occurred on the US Territory of Guam during 2009 to 2010, primarily in school-aged children. Methods: We implemented active surveillance in April 2010 during the outbreak peak and characterized the outbreak epidemiology. We administered third doses of MMR vaccine to eligible students aged 9–14 years in 7 schools with the highest attack rates (ARs) between May 18, 2010, and May 21, 2010. Baseline surveys, follow-up surveys and case-reports were used to determine mumps ARs. Adverse events postvaccination were monitored. Results: Between December 1, 2009, and December 31, 2010, 505 mumps cases were reported. Self-reported Pohnpeians and Chuukese had the highest relative risks (54.7 and 19.7, respectively) and highest crowding indices (mean: 3.1 and 3.0 persons/bedroom, respectively). Among 287 (57%) school-aged case-patients, 270 (93%) had ≥2 MMR doses. A third MMR dose was administered to 1068 (33%) eligible students. Three-dose vaccinated students had an AR of 0.9/1000 compared with 2.4/1000 among students vaccinated with ≤2 doses >1 incubation period postintervention, but the difference was not significant (P = 0.67). No serious adverse events were reported. Conclusions: This mumps outbreak occurred in a highly vaccinated population. The highest ARs occurred in ethnic minority populations with the highest household crowding indices. After the third dose MMR intervention in highly affected schools, 3-dose recipients had an AR 60% lower than students with ≤2 doses, but the difference was not statistically significant and the intervention occurred after the outbreak peaked. This outbreak may have persisted due to crowding at home and high student contact rates.


  • Open Access

    Measles in the United States during the Postelimination Era

    by Amy Parker Fiebelkorn, Susan B. Redd, Kathleen Gallagher, Paul A. Rota, Jennifer Rota, William Bellini, Jane Seward

    Background. Measles affected entire birth cohorts in the prevaccine era but was declared eliminated in the United States in 2000 because of a success


  • Open Access

    Challenges to Implementing Second‐Dose Varicella Vaccination during an Outbreak in the Absence of a Routine 2‐Dose Vaccination Requirement—Maine, 2006

    by Amy A. Parker, Meredith A. Reynolds, Jessica Leung, Meredith Anderson, Araceli Rey, Ismael R. Ortega‐Sanchez, D. Scott Schmid, Dalya Guris, Kathleen F. Gensheimer

    In June 2005, the Advisory Committee on Immunization Practices (ACIP) recommended administering a second dose of varicella vaccine during outbreaks,